James A. Bianco, M.D., President and Chief Executive Officer, is scheduled to speak at 12:30 p.m. ET as the Phase 3 immuno-oncology company advances IFx-2.0 and TBS-2025.
36d ago
verifying reliability
No specialized terms available for this topic.